ArticleEvidence-based complementary and alternative medicine : eCAM2013
Update on berberine in nonalcoholic Fatty liver disease.
Article in Evidence-based complementary and alternative medicine : eCAM, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Cholesterol Absorption Inhibition by Some Nutraceuticals.Recent advances in food, nutrition & agriculture · 2025Review
- Traditional Medicinal Plants as a Source of Inspiration for Osteosarcoma Therapy.Molecules (Basel, Switzerland) · 2022Review
- Expatiating the Pharmacological and Nanotechnological Aspects of the Alkaloidal Drug Berberine: Current and Future Trends.Molecules (Basel, Switzerland) · 2022Review
- Berberine Slows the Progression of Prediabetes to Diabetes in Zucker Diabetic Fatty Rats by Enhancing Intestinal Secretion of Glucagon-Like Peptide-2 and Improving the Gut Microbiota.Frontiers in endocrinology · 2021Article
- Medicinal Plants and Phytochemicals Regulating Insulin Resistance and Glucose Homeostasis in Type 2 Diabetic Patients: A Clinical Review.Advances in experimental medicine and biology · 2021Review
- Anti-inflammatory activity of berberine in non-alcoholic fatty liver disease via the Angptl2 pathway.BMC immunology · 2020Article
- The beneficial effects of nutraceuticals and natural products on small dense LDL levels, LDL particle number and LDL particle size: a clinical review.Lipids in health and disease · 2020Review
- Herbal drug discovery for the treatment of nonalcoholic fatty liver disease.Acta pharmaceutica Sinica. B · 2020Review
- Berberine attenuates hepatic oxidative stress in rats with non-alcoholic fatty liver disease via the Nrf2/ARE signalling pathway.Experimental and therapeutic medicine · 2019Article
- Berberine Protects against NEFA-Induced Impairment of Mitochondrial Respiratory Chain Function and Insulin Signaling in Bovine Hepatocytes.International journal of molecular sciences · 2018Article
- The Pathogenesis of Diabetes Mellitus by Oxidative Stress and Inflammation: Its Inhibition by Berberine.Frontiers in pharmacology · 2018Review
- An Insight into Ginsenoside Metabolite Compound K as a Potential Tool for Skin Disorder.Evidence-based complementary and alternative medicine : eCAM · 2018Review
- The Potential Mechanisms of Berberine in the Treatment of Nonalcoholic Fatty Liver Disease.Molecules (Basel, Switzerland) · 2016Review
- Metformin and metabolic diseases: a focus on hepatic aspects.Frontiers of medicine · 2015Review
- Metabolomics profiling to investigate the pharmacologic mechanisms of berberine for the treatment of high-fat diet-induced nonalcoholic steatohepatitis.Evidence-based complementary and alternative medicine : eCAM · 2015Article
- Berberine-loaded solid lipid nanoparticles are concentrated in the liver and ameliorate hepatosteatosis in db/db mice.International journal of nanomedicine · 2015Article
- Berberine in Combination with Insulin Has Additive Effects on Titanium Implants Osseointegration in Diabetes Mellitus Rats.Evidence-based complementary and alternative medicine : eCAM · 2015Article
- Modern approach to the clinical management of non-alcoholic fatty liver disease.World journal of gastroenterology · 2014Review
- Antioxidant and anti-inflammatory activities of berberine in the treatment of diabetes mellitus.Evidence-based complementary and alternative medicine : eCAM · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Berberine (BBR), an active ingredient from nature plants, has demonstrated multiple biological activities and pharmacological effects in a series of metabolic diseases including nonalcoholic fatty liver disease (NAFLD). The recent literature points out that BBR may be a potential drug for NAFLD in both experimental models and clinical trials. This review highlights important discoveries of BBR in this increasing disease and addresses the relevant targets of BBR on NAFLD which links to insulin pathway, adenosine monophosphate-activated protein kinase (AMPK) signaling, gut environment, hepatic lipid transportation, among others. Developing nuanced understanding of the mechanisms will help to optimize more targeted and effective clinical application of BBR for NAFLD.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.